"Genomics may be the 'next big thing' after the Internet and biotech. Finding those who can make money early onwill likely pay dividends to investors," expla]in small cap growth stock specialist Jim Oberweis, Jr.

In his The Oberweis Report, he explains the "politics" behind this bullish scenario as well as his top pick for log-term investors seeking exposure to the developing healthcare technologies if genomics and personalized medicine.

"We believe that the biotech boom was a direct consequence of rising National Health Institute (NIH) funding, cheap equity capital, and the ability to patent NIH-funded discoveries. And we see that happening again.

For 25 years, Steven Halpern, editor of TheStockAdvisors.com, has surveyed the leading financial newsletter advisors asking for their favorite stocks for the coming year. This article is one of 100+ ideas in the Best Stocks for 2008 report.

"Our favorite speculative pick for 2008 is (NASDAQ: IVGN)," says Daniel Frishberg, editor of The MoneyMan Report and host of BizRadio.

"Invitrogen is a $4.5 billion company that markets tools in kit form and provides other research products and services to corporate, academic, and government entities. The company has over 25,000 products.

"The company is also involved in stem cells, which are cells in an early stage human embryo that have the potential to turn into any other type of cells, e.g., heart, nerve, kidney, pancreas, etc.

"There has been much debate about stem cell research due to the killing of an embryo. However, a major breakthrough suggests that stem cells can be created from your own skin cells.